SCHEMBL3621333

SCHEMBL3621333

Cc1cc(O)c(F)cc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
GPR35 Q9HC97 4/20 0.47
MAPT P10636 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
RECQL P46063 3/20 0.44
TTR P02766 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
KDM4E B2RXH2 2/20 0.44
CYP2C9 P11712 2/20 0.44
HPGD P15428 2/20 0.44
MAPK1 P28482 2/20 0.44
PMP22 Q01453 2/20 0.44
HIF1A Q16665 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CYP1A2 P05177 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
TSHR P16473 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10342981 0.92 GPR35 (0.47) ALDH1A1GPR35MAPTSMN1; SMN2MEN1
SCHEMBL4137957 0.85 GPR35 (0.48) ALDH1A1GPR35MAPTSMN1; SMN2MEN1
SCHEMBL7937707 0.84 SNCA (0.55) ALDH1A1GPR35MAPTSMN1; SMN2MEN1
SCHEMBL440478 0.84 ALDH1A1 (0.53) ALDH1A1GPR35MAPTSMN1; SMN2RECQL
SCHEMBL29525219 0.84 ALDH1A1 (0.53) ALDH1A1GPR35MAPTSMN1; SMN2RECQL
SCHEMBL29510944 0.84 SNCA (0.55) ALDH1A1GPR35MAPTSMN1; SMN2MEN1
SCHEMBL1828398 0.82 ALDH1A1 (0.51) ALDH1A1GPR35MAPTSMN1; SMN2RECQL
SCHEMBL2413345 0.82 TDP1 (0.50) ALDH1A1GPR35MAPTSMN1; SMN2MEN1
SCHEMBL29479185 0.82 ALDH1A1 (0.51) ALDH1A1GPR35MAPTSMN1; SMN2RECQL
SCHEMBL8580180 0.82 GPR35 (0.52) ALDH1A1GPR35MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4477271-B1 N-(PHENYL)-5-(HETEROARYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TNIK INHIBITORS FOR USE IN THE TREATMENT OF CANCER KOREA RES INST CHEMICAL TECH (KR) 2026-05-13 EP disclosed
CN-115697990-B Indazole-based compounds and related methods of use 阿维纳斯企业公司 2025-06-13 CN disclosed
US-20250114356-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2025-04-10 US disclosed
EP-4477271-A2 COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF Korea Research Institute of Chemical Technology (KR) 2024-12-18 EP disclosed
EP-3749648-B1 N-(PHENYL)-5-(PHENYL)-1H-PYRAZOL-3-AMINE DERIVATIVES AS TNIK INHIBITORS FOR USE IN THE TREATMENT OF CANCER KOREA RES INST CHEMICAL TECH (KR) 2024-10-30 EP disclosed
US-12053469-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-08-06 US disclosed
EP-3426246-B1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2024-05-01 EP disclosed
CN-111836801-B Compounds for inhibiting TNIK and medical use thereof 韩国化学硏究院 2024-02-02 CN disclosed
US-11767297-B2 Compounds for inhibiting TNIK and medical uses thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2023-09-26 US disclosed
US-11767297-B2 Compounds for inhibiting TNIK and medical uses thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2023-09-26 US disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
CN-101484420-A Indoles as 5-HT 6 modulators BIOVITRUM AB PUBL (SE) 2009-07-15 CN disclosed
EP-2046741-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (publ) (SE) 2009-04-15 EP disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed
WO-2008003703-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO disclosed
EP-0505322-B1 Aminoguanidines CIBA GEIGY AG (CH) 1998-09-09 EP disclosed
US-5510353-A TREATING IRRITABLE BOWEL SYNDROME, GASTROESOPHAGEAL REFLUX DISEASE, CONSTIPATION, MIGRAINE HEADACHES SANDOZ LTD. (CH) 1996-04-23 US disclosed
EP-0505322-A1 Aminoguanidines SANDOZ LTD. (CH) 1992-09-23 EP disclosed
WO-1992007829-A1 INDOLE-3-METHANAMINES USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS THE UPJOHN COMPANY (US) 1992-05-14 WO disclosed
US-4087444-A Amides as ovulation inhibitors ELI LILLY AND COMPANY (US) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114356-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 ALDH1A1 3531/4885GPR35 2485/4885MAPT 403/4885
US-20080032968-A1 New compounds HTR6, HTR1B, HTR1A ALDH1A1 917/4885GPR35 150/4885MAPT 1591/4885
US-11767297-B2 Compounds for inhibiting TNIK and medical uses thereof TNNI3K, TNK1, TNIK ALDH1A1 4519/4885GPR35 3256/4885MAPT 3588/4885
US-12053469-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, MDM2 ALDH1A1 3531/4885GPR35 2485/4885MAPT 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.